Spyre Therapeutics Prices $350.0 Million Underwritten Public Offering

Spyre Therapeutics priced a $350m underwritten common stock offering at $85/share, increasing share count and near-term supply. Such financings typically create dilution and can pressure the issuer's equity in the short run while strengthening the balance sheet and extending funding runway. Market impact is primarily idiosyncratic to the company, with limited broader read-through unless it signals wider biotech capital-markets re-opening.